Clinical Trial Update: MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK-0518 (raltegravir) intensification with histone deacetylase inhibition to deplete resting CD4+ T cell HIV infection; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: HIV Infections | Phase 2 | Status: TERMINATED | Results posted: 2011-10-25